Fig. 3

Plot of CD8⁺-positive cells per mm² of tumor area and CD8⁺/CD4⁺ as quantified by immunohistochemistry in the tumor (a) and in the stroma (b). Matched baseline and post-treatment measurements are connected by a line. In total, 13 patients had matched post-treatment biopsies. Aza, azacitidine plus pembrolizumab (Arm A); Rom, romidepsin plus pembrolizumab (Arm B), Aza + Rom, azacitidine plus romidepsin plus pembrolizumab (Arm C)